Literature DB >> 23503778

[Imaging diagnostics of hyperparathyroidism].

S Delorme1, C Zechmann, U Haberkorn.   

Abstract

Primary hyperparathyroidism is diagnosed by the presence of hypercalcemia, hypercalciuria and elevated serum levels of parathyroid hormone and is treated surgically by removal of the enlarged gland. Both ultrasound and 99m-Tc-MIBI scintigraphy are used to localize enlarged parathyroid glands. With sonography, enlarged parathyroid glands are hypoechoic and are most frequently found dorsally or caudally to the thyroid and medially to the carotid arteries. Ectopic parathyroid glands in the mediastinum can be detected by scintigraphy only. Computed tomography and magnetic resonance imaging are not primarily indicated. The sensitivity of ultrasound is 90% at best. Causes for false negative ultrasound examinations are ectopic glands in the mediastinum, small glands weighing less than 200 mg and large goiters which make assessment of the retrothyroid space difficult. Ultrasound and scintigraphy in combination can achieve a sensitivity of more than 90%. A combination of both is indicated prior to minimally invasive resection and in cases of recurrence or persistence of hyperparathyroidism after resection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23503778     DOI: 10.1007/s00117-012-2458-1

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  33 in total

1.  Surgical therapy for primary hyperparathyroidism in patients with previous thyroid surgery.

Authors:  C Profanter; A Klingler; S Strolz; G J Wetscher; R Prommegger; E Bodner; G Riccabona
Journal:  Am J Surg       Date:  1999-11       Impact factor: 2.565

Review 2.  Clinical practice. Primary hyperparathyroidism.

Authors:  Claudio Marcocci; Filomena Cetani
Journal:  N Engl J Med       Date:  2011-12-22       Impact factor: 91.245

Review 3.  Diagnosis and management of primary hyperparathyroidism.

Authors:  Shelley Pallan; Mohammed Omair Rahman; Aliya A Khan
Journal:  BMJ       Date:  2012-03-19

4.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

5.  Procedure guideline for parathyroid scintigraphy. Society of Nuclear Medicine.

Authors:  B S Greenspan; M L Brown; G L Dillehay; M McBiles; M P Sandler; J E Seabold; J C Sisson
Journal:  J Nucl Med       Date:  1998-06       Impact factor: 10.057

6.  A comprehensive evaluation of perioperative adjuncts during minimally invasive parathyroidectomy: which is most reliable?

Authors:  Herbert Chen; Eberhard Mack; James R Starling
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

7.  [Hereditary variants of primary hyperparathyroidism--MEN1, MEN2, HPT-JT, FHH, FIHPT].

Authors:  K Frank-Raue; G Leidig-Bruckner; A Lorenz; S Rondot; C Haag; E Schulze; M Büchler; F Raue
Journal:  Dtsch Med Wochenschr       Date:  2011-09-13       Impact factor: 0.628

8.  Parathyroid glands: combination of (99m)Tc MIBI scintigraphy and US for demonstration of parathyroid glands and nodules.

Authors:  M L De Feo; S Colagrande; C Biagini; A Tonarelli; G Bisi; L Vaggelli; D Borrelli; P Cicchi; F Tonelli; A Amorosi; M Serio; M L Brandi
Journal:  Radiology       Date:  2000-02       Impact factor: 11.105

9.  Does intraoperative quick parathyroid hormone assay improve the results of parathyroidectomy?

Authors:  Daishu Miura; Nobuyuki Wada; Cumhur Arici; Eugene Morita; Quan-Yang Duh; Orlo H Clark
Journal:  World J Surg       Date:  2002-04-30       Impact factor: 3.352

10.  Improved localization of sestamibi imaging at high-volume centers.

Authors:  Michael C Singer; Darko Pucar; Manoj Mathew; David J Terris
Journal:  Laryngoscope       Date:  2012-09-24       Impact factor: 3.325

View more
  2 in total

Review 1.  [Endocrine tumors: clinical overview].

Authors:  G Leidig-Bruckner
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

2.  [Endocrine tumors and their therapy].

Authors:  S Delorme; G Leidig-Bruckner; T Wilhelm
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.